About Acyl-CoA dehydrogenase family member 11
Acyl-CoA dehydrogenase family member 11 (ACAD11) is a protein
from Homo sapiens identified by UniProt accession
Q709F0, 780 residues long.
MolForge cross-references it against 0 known binders and
93 disease associations.
Target properties
| Protein name | Acyl-CoA dehydrogenase family member 11 |
| UniProt accession | Q709F0 |
| Gene | ACAD11 |
| Organism | Homo sapiens |
| Length | 780 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (2)
DrugCentral-linked approved drugs that act on this protein.
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q709F0-F1 | alphafold | PREDICTED | 90.70 | — |
Amino-acid sequence (780 residues)
MKPGATGESD LAEVLPQHKF DSKSLEAYLN QHLSGFGAER EATLTIAQYR AGKSNPTFYL QKGFQTYVLR KKPPGSLLPK AHQIDREFKV QKALFSIGFP VPKPILYCSD TSVIGTEFYV MEHVQGRIFR DLTIPGLSPA ERSAIYVATV ETLAQLHSLN IQSLQLEGYG IGAGYCKRQV STWTKQYQAA AHQDIPAMQQ LSEWLMKNLP DNDNEENLIH GDFRLDNIVF HPKECRVIAV LDWELSTIGH PLSDLAHFSL FYFWPRTVPM INQGSYSENS GIPSMEELIS IYCRCRGINS ILPNWNFFLA LSYFKMAGIA QGVYSRYLLG NNSSEDSFLF ANIVQPLAET GLQLSKRTFS TVLPQIDTTG QLFVQTRKGQ EVLIKVKHFM KQHILPAEKE VTEFYVQNEN SVDKWGKPLV IDKLKEMAKV EGLWNLFLPA VSGLSHVDYA LIAEETGKCF FAPDVFNCQA PDTGNMEVLH LYGSEEQKKQ WLEPLLQGNI TSCFCMTEPD VASSDATNIE CSIQRDEDSY VINGKKWWSS GAGNPKCKIA IVLGRTQNTS LSRHKQHSMI LVPMNTPGVK IIRPLSVFGY TDNFHGGHFE IHFNQVRVPA TNLILGEGRG FEISQGRLGP GRIHHCMRTV GLAERALQIM CERATQRIAF KKKLYAHEVV AHWIAESRIA IEKIRLLTLK AAHSMDTLGS AGAKKEIAMI KVAAPRAVSK IVDWAIQVCG GAGVSQDYPL ANMYAITRVL RLADGPDEVH LSAIATMELR DQAKRLTAKI
Explore Acyl-CoA dehydrogenase family member 11 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets